Search | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 1 result.

- Journal article
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu, Andrew X Park, Joon Oh Ryoo, Baek-Yeol Yen, Chia-Jui Poon, Ronnie Pastorelli, Davide Blanc, Jean-Frederic Chung, Hyun Cheol Baron, Ari D Pfiffer, Tulio Eduardo Flesch Okusaka, Takuji Kubackova, Katerina Trojan, Jorg Sastre, Javier Chau, Ian Chang, Shao-Chun Abada, Paolo B Yang, Ling Schwartz, Jonathan D Kudo, Masatoshi Borbath, Ivan[UCL] (2015) The Lancet Oncology — Vol. 16, no. 7, p. 859-870 (2015)